2018
DOI: 10.1002/minf.201800053
|View full text |Cite
|
Sign up to set email alerts
|

Flap‐site Fragment Restores Back Wild‐type Behaviour in Resistant Form of HIV Protease

Abstract: HIV-1 protease (HIV-PR) performs a vital step in the virus life cycle which makes it an excellent target for drug therapy. However, due to the error-prone of HIV reverse transcriptase, mutations in HIV-PR often occur, inducing drug-resistance to inhibitors. Some HIV-PR mutations can make the flaps of the enzyme more flexible thus increasing the flaps opening rate and inhibitor releasing. It has been shown that by targeting novel binding sites on HIV-PR with small molecules, it is possible to alter the equilibr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
2
1

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 25 publications
0
1
0
Order By: Relevance
“…We have previously applied this theory to understand the action mechanism of human dihydrofolate reductase inhibitors, , BACE1 inhibitors, , D2 dopamine receptor ligands, sphingosine kinase 1 (Sphk1) inhibitors, and HIV-1 protease flap fragments, among others.…”
Section: Introductionmentioning
confidence: 99%
“…We have previously applied this theory to understand the action mechanism of human dihydrofolate reductase inhibitors, , BACE1 inhibitors, , D2 dopamine receptor ligands, sphingosine kinase 1 (Sphk1) inhibitors, and HIV-1 protease flap fragments, among others.…”
Section: Introductionmentioning
confidence: 99%